Hidradenitis Suppurativa in Children and Adolescents: A Review of Treatment Options

Peter Riis Mikkelsen; Gregor B E Jemec

doi:10.1007/s40272-014-0091-3

Hidradenitis Suppurativa in Children and Adolescents: A Review of Treatment Options

Peter Riis Mikkelsen, Gregor B E Jemec

Institut for Klinisk Medicin

30 Citationer (Scopus)

Abstract

Hidradenitis suppurativa (HS) is a burdensome disease and has the potential to affect the life course of patients. It is a rare disease in children, and the recorded literature is correspondingly scarce. This article reviews the therapeutic options for HS in children and adolescents, and highlights particular differences or challenges with treating patients in this age group compared with adults. The work-up of paediatric patients with HS should include considerations of possible endocrine co-morbidities and obesity. Medical therapy of lesions may include topical clindamycin. Systemic therapy may include analgesics, clindamycin and rifampicin, finasteride, corticosteroids or tumour necrosis factor alpha (TNFα) blockers. Superinfections should be appropriately treated. Scarring lesions generally require surgery.

Originalsprog	Engelsk
Tidsskrift	Paediatric Drugs
Vol/bind	16
Udgave nummer	6
Sider (fra-til)	483-489
Antal sider	7
ISSN	1174-5878
DOI	https://doi.org/10.1007/s40272-014-0091-3
Status	Udgivet - 2 dec. 2014

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1007/s40272-014-0091-3

Citationsformater

@article{bbeff601834f435eb12f13cc90bb3866,

title = "Hidradenitis Suppurativa in Children and Adolescents: A Review of Treatment Options",

abstract = "Hidradenitis suppurativa (HS) is a burdensome disease and has the potential to affect the life course of patients. It is a rare disease in children, and the recorded literature is correspondingly scarce. This article reviews the therapeutic options for HS in children and adolescents, and highlights particular differences or challenges with treating patients in this age group compared with adults. The work-up of paediatric patients with HS should include considerations of possible endocrine co-morbidities and obesity. Medical therapy of lesions may include topical clindamycin. Systemic therapy may include analgesics, clindamycin and rifampicin, finasteride, corticosteroids or tumour necrosis factor alpha (TNFα) blockers. Superinfections should be appropriately treated. Scarring lesions generally require surgery.",

author = "Mikkelsen, {Peter Riis} and Jemec, {Gregor B E}",

year = "2014",

month = dec,

day = "2",

doi = "10.1007/s40272-014-0091-3",

language = "English",

volume = "16",

pages = "483--489",

journal = "Paediatric Drugs",

issn = "1174-5878",

publisher = "Adis International Ltd",

number = "6",

}

TY - JOUR

T1 - Hidradenitis Suppurativa in Children and Adolescents

T2 - A Review of Treatment Options

AU - Mikkelsen, Peter Riis

AU - Jemec, Gregor B E

PY - 2014/12/2

Y1 - 2014/12/2

N2 - Hidradenitis suppurativa (HS) is a burdensome disease and has the potential to affect the life course of patients. It is a rare disease in children, and the recorded literature is correspondingly scarce. This article reviews the therapeutic options for HS in children and adolescents, and highlights particular differences or challenges with treating patients in this age group compared with adults. The work-up of paediatric patients with HS should include considerations of possible endocrine co-morbidities and obesity. Medical therapy of lesions may include topical clindamycin. Systemic therapy may include analgesics, clindamycin and rifampicin, finasteride, corticosteroids or tumour necrosis factor alpha (TNFα) blockers. Superinfections should be appropriately treated. Scarring lesions generally require surgery.

AB - Hidradenitis suppurativa (HS) is a burdensome disease and has the potential to affect the life course of patients. It is a rare disease in children, and the recorded literature is correspondingly scarce. This article reviews the therapeutic options for HS in children and adolescents, and highlights particular differences or challenges with treating patients in this age group compared with adults. The work-up of paediatric patients with HS should include considerations of possible endocrine co-morbidities and obesity. Medical therapy of lesions may include topical clindamycin. Systemic therapy may include analgesics, clindamycin and rifampicin, finasteride, corticosteroids or tumour necrosis factor alpha (TNFα) blockers. Superinfections should be appropriately treated. Scarring lesions generally require surgery.

U2 - 10.1007/s40272-014-0091-3

DO - 10.1007/s40272-014-0091-3

M3 - Review

C2 - 25234961

SN - 1174-5878

VL - 16

SP - 483

EP - 489

JO - Paediatric Drugs

JF - Paediatric Drugs

IS - 6

ER -

Hidradenitis Suppurativa in Children and Adolescents: A Review of Treatment Options

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater